What? Quote: "Pharmacyte gets no advantage by releasing a PR that Austrianova got the GMP approval. If the stock price goes up, Pharmacyte makes no money."
Maybe look at the financials and see all the (S-3) sales.
The principal source of our cash is the sale of our common stock as part of our S-3 Registration Statement.
The Company continues to acquire funds through the Company’s S-3 Registration Statement pursuant to which its exclusive placement agent, Chardan Capital Markets, LLC (“Chardan” sells shares of common stock “at-the-market” which is structured to provide up to $50 million dollars to the Company less certain commissions.
On November 28, 2014, the Company sold 2,777,778 shares of common stock under the S-3 Registration Statement. The issuance of the shares provided the Company approximately $465,000.? From February 1, 2015 to March 13, 2015, the Company sold 4,310,188 shares of common stock under the S-3 Registration Statement. The issuance of the shares provided the Company approximately $520,553.? From May 1, 2015 to July 16, 2015, the Company issued 9,328,713 shares of common stock under the S-3 Registration Statement. The issuance of the shares provided the Company approximately $1,220,000. The Company currently has $2,900,000 in cash as a result of the sales of common stock under the S-3 Registration Statement.? http://www.sec.gov/Archives/edgar/data/1157075/000101968715002894/pharmacyte_10k-043015.htm ? On October 17, 2014, we filed a Prospectus (“Prospectus”) with the United States Securities and Exchange Commission (“SEC”) pursuant to which we disclosed that we may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants or units having a maximum aggregate offering price of $50,000,000. We also explain that when we decide to sell a particular class or series of securities, we would provide specific terms of the offered securities in a Prospectus Supplement.
On November 12, 2014, we filed a Prospectus Supplement (“Prospectus Supplement”) with the SEC. The Prospectus Supplement described the terms of the Chardan Agreement and added to and updated information contained in the Prospectus. We also described that the sales of our common stock, if any, under the Prospectus Supplement and the Prospectus would be made by any method permitted that is deemed an “at the market” offering as defined in Rule 415 under the Securities Act of 1933, as amended (“Securities Act”), including by means of ordinary brokers’ transactions at market prices, in block transactions or as otherwise agreed by Chardan and us. Under this arrangement, Chardan will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices.
On December 2, 2014, we amended the Prospectus Supplement with the SEC. In the amended Prospectus Supplement, we disclosed that the sales of our common stock under the Prospectus Supplement may include sales at a fixed price as agreed by Chardan and us. Under this arrangement, Chardan will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices.
The company has a fidicary duty to maximize value for its shareholders so witholding material information would work against them in that regard and would be most likely illegal.
cGMP approval would legitimize the company and there would be other ways to raise capital without diluting the stock.
News 
Market Data 
Discover 
